OpenAI researcher Miles Wang is leaving OpenAI to launch a new AI-driven drug discovery company, aiming to raise about $200 million at a roughly $2 billion valuation.

TechCrunch reports Lightspeed is in talks to lead the funding round, though terms could evolve and there has been no formal comment yet.

Wang, who joined OpenAI in 2024 after Harvard, helped co-author work on automating scientific discovery with AI prior to founding the new venture.

Investors face risks such as long timelines to revenue due to clinical trials and regulatory approvals, intensified competition, and the challenge of proving AI models can reliably identify viable drug candidates.

The competitive landscape includes Isomorphic Labs’ partnership with Eli Lilly and Recursion Pharmaceuticals, signaling a crowded field of AI-driven biotech startups.

The report cites industry context and signals from familiar sources, with no official confirmations from all parties yet.

The trend shows increasing concentration of capital and talent in AI-powered biomedicine, potentially accelerating pharmaceutical R&D efficiency and commercialization.

If the deal closes on reported terms, it would be among the largest biotech debut rounds, underscoring investor confidence in AI-enabled biology.

Industry supporters argue AI can speed drug discovery, including repurposing existing safe compounds, but the field remains nascent and faces regulatory hurdles and uncertainty over translating predictions into clinical efficacy.

Investor interest in AI for biomedicine is rising, with recent funding activity seen in Chai Discovery and Isomorphic Labs, highlighting a trend toward AI-enabled drug development.

The broader AI-bio funding trend includes Chai Discovery’s $400 million round at a $3.8 billion valuation and Isomorphic Labs’ $2.1 billion Series B, illustrating enthusiasm for AI-driven drug discovery.